Logo Image
News
All NewsBio/Pharma NewsIndustry NewsSupplier NewsEvents
Multimedia
All VideosAsk the ExpertBehind the HeadlinesBuy, Sell, HoldDrug DigestPeer ExchangePivotal PapersShorts
Publication
Conferences
Conference ListingLatest Conference Content
More
Resources
Podcast SeriesBiopharma InsightsPartnersSponsored PodcastsSponsored VideosSponsored eBooksToolkitsWhitepapers
Webcasts
Event Calendar

Subscribe

  • News
  • Multimedia
  • Publication
  • Conferences
  • Resources
  • Subscribe
  • Webcasts
  • Event Calendar
  • BioBusiness
    • Partnerships
    • Funding and Investments
    • Intellectual Property & Patents
    • Biologic Drugs in Development
    • Mergers and Acquisitions
  • BioPharm Products
  • BioPharm Sponsored Ad
  • Biopharmaceutical Analysis
    • Analytical Best Practices
    • Analytical Methods
    • Lab Furnishings and Equipment
    • Contract Analytical Services
    • Finished Product Analysis
    • Drug Substance Analysis
    • Biopharmaceutical Analysis: GC-MS
    • Biopharmaceutical Analysis: Mass Spectrometry
    • Biopharmaceutical Analysis: ICP-MS
    • Biopharmaceutical Analysis: NMR
    • Biopharmaceutical Analysis: Raman
    • Biopharmaceutical Analysis: Gas Chromatography
    • Biopharmaceutical Analysis: LC-MS
    • Biopharmaceutical Analysis: HPLC/UHPLC
    • Analytical Instrumentation
  • Biosimilars and Biobetters
  • Deals, Development and Manufacturing
  • Development
    • Formulation
    • Process Validation
    • Drug Delivery
    • Process Development
    • Scale Up
    • Excipients
    • API Synthesis and Manufacturing, Large Molecule
    • Formulation and Drug Delivery, Combination Drugs
    • Early Phase Development
    • Formulation and Drug Delivery, Biologic Drugs
    • Formulation and Drug Delivery, Parenterals
    • Formulation and Drug Delivery, Specialty Dosage Forms
    • Formulation and Drug Delivery, Controlled Release
    • Formulation and Drug Delivery, Liquids
    • Formulation and Drug Delivery, Solid Dosage
    • Formulation and Drug Delivery, Other
  • Discovery Pipeline
  • Disposables Advisor
  • Downstream Processing
    • Viral Clearance
    • Manufacturing, Separation and Purification
    • Manufacturing Equipment, Downstream Processing
    • Manufacturing, Process Chromatography
  • Elements of Biopharmaceutical Production
  • From the CEO
  • From the Editor
  • Inside Standards
  • Interphex Keynote Sessions
  • Manufacturing
    • Manufacturing, Monoclonal Antibodies
    • Manufacturing Systems, Single-Use
    • Vaccine Development and Manufacturing
    • Manufacturing, Aseptic Processing
    • Manufacturing, Fill/Finish
    • Facility Design and Engineering
    • Process Control, Automation, and PAT
    • Supply Chain/Logistics
    • Manufacturing Best Practices
    • Information Technology
    • Technology Transfer
    • Manufacturing Equipment, Upstream Processing
    • Manufacturing Equipment, Biologics
    • Cleanroom Equipment and Supplies
    • Manufacturing, Parenterals and Injectables
    • Clinical Trial Materials
    • Manufacturing, Biosimilars and Biobetters
    • Manufacturing, Lyophilization
    • Manufacturing, Combination Drugs
    • Manufacturing, Solid Dosage Drugs
    • Manufacturing, Topical Drugs
    • Manufacturing, Biologics
    • Manufacturing, Specialty Dosage Forms
    • Manufacturing, Nucleic Acids
    • Manufacturing, Liquid Drug Products
    • Manufacturing, Drug Products
    • Manufacturing, Cell Therapies
    • Manufacturing, Recombinant Proteins
    • Manufacturing, Continuous Biologics Processing
    • Manufacturing, Gene Therapies
    • Packaging, Labeling, and Distribution Systems
  • Outsourcing
    • Clinical Trial Services
    • Perspectives on Outsourcing
    • Contract Services, Regulatory Consulting
    • Contract Packaging, Logistics, and Distribution
    • Contract Manufacturing, Sterile, Aseptic Processing
    • Contract Manufacturing, Biopharmaceutical Production
    • Contract Manufacturing, Drug Substance, API
    • Contract Manufacturing, Finished Drug Product
    • Contract Manufacturing, General
    • Contract Services, Formulation and Drug Delivery
  • Peer-Reviewed Research
  • Pharmacopoeial Compliance Series
  • Quality/GMPs
    • Ask the Expert
    • Regulatory/GMP Compliance
    • Compliance Notes
    • Regulatory Beat
    • European Regulatory Watch
    • Adverse Events and Recalls
    • Regulatory/GMP Compliance, Europe
    • Regulatory/GMP Compliance, Emerging Markets
    • Audits and Inspections
    • Anticounterfeiting, Track and Trace Systems
    • Quality by Design
    • Compendial Compliance
    • Standard Operating Procedures (SOPs)
    • Quality Control/Quality Assurance
    • Regulatory Filings and Submissions
    • Regulatory Authority Actions
  • Therapeutic Specific Areas
  • Upstream Processing
    • Manufacturing, Cell-Line Selection
    • Manufacturing, Expression Systems
    • Manufacturing, Cell Culture and Fermentation
  • Viewpoints
  • Weighing Up Big Pharma
Spotlight -
Analytics|
Development|
Downstream Processing|
Manufacturing|
Outsourcing|
Quality/GMPs|
Upstream Processing
Advertisement

Richard Bunnell, PhD

Advertisement

Articles by Richard Bunnell, PhD

Table1-809073-1408542834091.jpg

Overcoming Challenges in the Reconstitution of a High-Concentration Protein Drug Product

ByLeu-Fen H. Lin, PhD,Richard Bunnell, PhD
March 1st 2013

The authors present approaches used to reduce reconstitution time of a lyophilized high-concentration protein drug product.

Table-1_t-791282-1408596013718.jpg

Moisture Matters in Lyophilized Drug Product

ByLeu-Fen H. Lin, PhD,Richard Bunnell, PhD
October 1st 2012

Using an alternate moisture-generation method may provide more accurate data for regulatory submissions.

Advertisement

Latest Updated Articles

  • Table1-809073-1408542834091.jpg
    Overcoming Challenges in the Reconstitution of a High-Concentration Protein Drug Product

    March 1st 2013

  • Table-1_t-791282-1408596013718.jpg
    Moisture Matters in Lyophilized Drug Product

    October 1st 2012



Advertisement
Advertisement

Trending on BioPharm International

1

Caldera’s IL-23p19×TL1A Bispecific CLD-423 Shows 40-Day Half-Life in Phase 1a, Supporting Dosing Every 8 to 12 Weeks

2

China Grants Ivonescimab Priority Review in Biliary Tract Cancer

3

FAQ: What FDA’s Individualized Gene Editing Draft Guidance Means for Developers

4

VeonGen Aligns with FDA on Phase 3 Design for Stargardt Gene Therapy

5

The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific

  • About Us
  • Advertise
  • Editorial Information
  • Contact Us
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us